ReviewCells2020
miR-205: A Potential Biomedicine for Cancer Therapy.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 82 citations in OpenAlex.
- The LncRNA GAS5/miR-205 ceRNA axis regulates fibroblast activation and may contribute to hypertrophic scarring.Molecular biology reports · 2026Article
- Advances in the biological functions of miR‑205 in various diseases (Review).Molecular medicine reports · 2026Review
- miRNA gene mutations commonly disrupt the proper functioning of miRNA genes.Science advances · 2026Article
- Mapping Non-Coding Epimutations in Breast Cancer: Advancing Epigenetics Towards Precision Medicine.Sub-cellular biochemistry · 2026Review
- miR-205 Enhances Sensitivity to Genotoxic Agents in HNSCC Cells and Blocks Sphingosine Kinase 2 Action in Tumorigenicity.ACS omega · 2025Article
- MiR-205-5p downregulation and circ_100290 upregulation in glioblastoma patients are associated with tumor aggressiveness.Discover oncology · 2025Article
- Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.Oncogene · 2025Review
- Identification of miRNA-mRNA Co-expression by network analysis in dengue virus infection.Virusdisease · 2025Article
- Prognostic model identification of ribosome biogenesis-related genes in pancreatic cancer based on multiple machine learning analyses.Discover oncology · 2025Article
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- Profiling the cell-specific small non-coding RNA transcriptome of the human placenta.Scientific reports · 2025Article
- Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.Non-coding RNA research · 2025Review
- Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells.Current gene therapy · 2025Review
- The progress of miR-205 regulating apoptosis in cancer.Frontiers in oncology · 2025Review
- Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: a retrospective, exploratory analysis.Scientific reports · 2024Article
- Suppression of Metastasis of Colon Cancer to Liver in Mouse Models by Pretreatment with Extracellular Vesicles Derived fromInternational journal of molecular sciences · 2024Article
- Modulation of miR-205 expression using aRSC advances · 2024Article
- Deep Learning-Based Identification of Tissue of Origin for Carcinomas of Unknown Primary Using MicroRNA Expression: Algorithm Development and Validation.JMIR bioinformatics and biotechnology · 2024Article
- Review
- How MicroRNAs Command the Battle against Cancer.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
microRNAs (miRNAs) are a class of small non-coding RNAs that regulate the expression of their target mRNAs post transcriptionally. miRNAs are known to regulate not just a gene but the whole gene network (signaling pathways). Accumulating evidence(s) suggests that miRNAs can work either as oncogenes or tumor suppressors, but some miRNAs have a dual nature since they can act as both. miRNA 205 (miR-205) is one such highly conserved miRNA that can act as both, oncomiRNA and tumor suppressor. However, most reports confirm its emerging role as a tumor suppressor in many cancers. This review focuses on the downregulated expression of miR-205 and discusses its dysregulation in breast, prostate, skin, liver, gliomas, pancreatic, colorectal and renal cancers. This review also confers its role in tumor initiation, progression, cell proliferation, epithelial to mesenchymal transition, and tumor metastasis. Restoration of miR-205 makes cells more sensitive to drug treatments and mitigates drug resistance. Additionally, the importance of miR-205 in chemosensitization and its utilization as potential biomedicine and nanotherapy is described. Together, this review research article sheds a light on its application as a diagnostic and therapeutic marker, and as a biomedicine in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.